Interim Analysis Shows High Efficacy Rate for the mRNA-1273 Vaccine
It was announced today that the Moderna COVID-19 vaccine trial “has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.” This is based on the first interim analysis of the data, conducted by an independent, NIH-appointed Data Safety Monitoring Board. Of the 30,000 participants enrolled in the trail, one half received the vaccine and one half received a placebo. There were 95 cases of COVID-19 in the study population, 90 from the placebo group and only 5 from those who received the vaccine, mRNA-1273. 12 of these cases were defined as severe, all of which occurred in the placebo arm. Our UCLA Vine Street Clinic is one of nearly 100 sites across the country conducting the trial. Our mission is to advance the prevention and treatment of chronic illnesses, especially in communities with health disparities, which have been hit especially hard by this virus. These are promising results and we are committed maintaining a high level of scientific rigor as we continue to monitor our study participants.
A detailed press release can be found here: https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy and reports from news agencies including CNN: https://www.cnn.com/2020/11/16/health/moderna-vaccine-results-coronavirus/index.html, NPR https://www.npr.org/sections/health-shots/2020/11/16/935239294/modernas-covid-19-vaccine-shines-in-clinical-trial, and Spectrum News 1 https://spectrumnews1.com/ca/san-fernando-valley-ventura/health/2020/11/17/moderna-vaccine–ucla-clinic-volunteer-shares-experience-in-trial.